On June 25th, Gelunhui reported that Shenzhen Salubris Pharmaceuticals (002294.SZ), a subsidiary of the company, recently learned that the company's biopharmaceutical product "Injection Teriparatide" (project code: SAL056) under development by its subsidiary, Suzhou Salubris Pharmaceuticals Co., Ltd., has been accepted for listing application by the National Medical Products Administration.

SAL056 is a long-acting bone-forming promoter that is injected subcutaneously once a week and is intended to treat postmenopausal osteoporosis in women at high risk of fractures. There are currently no products of the same specifications and usage in China. If SAL056 is approved for listing, it will greatly improve access to treatment for patients.